Yusuke Nakamura to Cancer Vaccines
This is a "connection" page, showing publications Yusuke Nakamura has written about Cancer Vaccines.
Connection Strength
5.584
-
Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.
Score: 0.650
-
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
Score: 0.631
-
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunol Invest. 2021 Jul; 50(5):562-579.
Score: 0.587
-
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012 Jul 09; 10:141.
Score: 0.337
-
Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
Score: 0.319
-
[Therapeutic cancer vaccines against gastro-intestinal cancer]. Nihon Shokakibyo Gakkai Zasshi. 2010 Aug; 107(8):1255-61.
Score: 0.294
-
Dendritic cell-derived exosomes induce monocyte antigen-presentation and immune amplification in neoantigen vaccine therapy. Front Immunol. 2025; 16:1565696.
Score: 0.205
-
Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Front Immunol. 2025; 16:1571182.
Score: 0.203
-
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Invest. 2022 Jul; 51(5):1498-1514.
Score: 0.159
-
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1371-1380.
Score: 0.127
-
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
Score: 0.126
-
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018 Mar; 109(3):542-549.
Score: 0.124
-
miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. Cancer Sci. 2017 Nov; 108(11):2229-2238.
Score: 0.121
-
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul; 108(7):1452-1457.
Score: 0.119
-
Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017 May; 50(5):1655-1662.
Score: 0.117
-
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
Score: 0.116
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
Score: 0.115
-
Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 01; 66(1):17-24.
Score: 0.113
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.109
-
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015 Jan 15; 21(2):312-21.
Score: 0.099
-
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res. 2014 Aug; 34(8):4201-5.
Score: 0.097
-
Guidance for peptide vaccines for the treatment of cancer. Cancer Sci. 2014 Jul; 105(7):924-31.
Score: 0.097
-
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
Score: 0.095
-
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
Score: 0.094
-
Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol. 2012 Jul; 42(7):591-600.
Score: 0.083
-
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010 Feb; 101(2):433-9.
Score: 0.070
-
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug; 100(8):1502-9.
Score: 0.068
-
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2268-70.
Score: 0.065
-
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
Score: 0.065
-
Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci. 2008 Nov; 99(11):2315-26.
Score: 0.065
-
From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb; 56(2):43-53.
Score: 0.062
-
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
Score: 0.021
-
Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6624-31.
Score: 0.015
-
Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
Score: 0.015